Johnson & Johnson Data Shows 50% Five-Year Progression-Free Rate for CARVYKTI

Key Facts

1Phase 2 CARTITUDE-2 data showed 50% of RRMM patients remained progression-free for five years after a single infusion of CARVYKTI without maintenance therapy.

Johnson & Johnson announced long-term data from its Phase 2 CARTITUDE-2 study showing that 50% of multiple myeloma patients remained progression-free for five years. PR Newswire reported that these patients maintained this response after a single infusion of CARVYKTI without the need for subsequent maintenance therapy, supporting its use in earlier lines of treatment.

The clinical results reinforce the company's oncology portfolio, though the findings were based on a limited subgroup of 20 patients. JNJ closed at $270.68 on September 24, 2026, having traded between a day high of $275.23 and a low of $269.01 during that session.